@phdthesis{Baumann2011,
  author    = {Baumann, Daniel},
  title     = {Charakterisierung der Pharmakokinetik und Pharmakodynamik intranasaler Glucocorticoide anhand von in vitro und ex vivo Modellen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-57230},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {Ziel dieser Arbeit war es die intranasalen pharmakokinetischen Abl{\"a}ufe nach topischer Applikation mittels in vitro und ex vivo Experimenten zu charakterisieren und ihre Auswirkungen auf die Pharmakodynamik zu beschreiben. Es wurden hierbei die nasal angewendeten Glucocorticoide Triamcinolonacetonid (TCA), Budesonid (Bud), Beclomethasondipropionat (BDP), Fluticasonpropionat (FP), Mometasonfuroat (MF) und Fluticasonfuroat (FF) sowie ihre handels{\"u}blichen Pr{\"a}parate Nasacort® (TCA), Budes® (Bud), ratioAllerg® (BDP), Flutide® Nasal (FP), Nasonex® (MF) und Avamys® (FF) untersucht. Zum Aufbringen der Wirkstoffsuspension auf die nasale Mukosa durch den Patienten kommen Dosierpumpsprays zum Einsatz, deren Dosiervorrichtung das Applikationsvolumen festlegen. Die Bestimmung des Spr{\"u}hstoßvolumens unterschiedlicher handels{\"u}blicher Pr{\"a}parate ergab Werte zwischen 56 und 147 µL/Spr{\"u}hstoß. Zum ersten Mal wurde eine Methode entwickelt, die es erm{\"o}glichte die Glucocorticoidkonzentration in den w{\"a}ssrigen {\"U}berst{\"a}nden handels{\"u}blicher Pr{\"a}parate zu bestimmen. Die Wasserl{\"o}slichkeit der unterschiedlichen Glucocorticoide sowie die galenische Zusammensetzung der Formulierungen konnten als m{\"o}gliche Einflussfaktoren f{\"u}r den bereits gel{\"o}sten Wirkstoffanteil ermittelt werden. Es konnte erstmals gezeigt werden, dass die L{\"o}slichkeit der Wirkstoffkristalle der lipophileren Substanzen wie BDP, FP, MF und FF durch das KNS signifikant verbessert wurde. Die L{\"o}slichkeit der hydrophileren Wirkstoffe wie TCA und Bud wurde durch das KNS dagegen nur leicht beeinflusst. Nach der Aufl{\"o}sung der Wirkstoffkristalle k{\"o}nnen die gel{\"o}sten Molek{\"u}le zur cytoplasmatischen Zielstruktur, dem Glucocorticoidrezeptor diffundieren und spezifisch binden. Neben der Rezeptorbindung erfolgt auch eine unspezifische Bindung an Nasengewebe. So wurde zun{\"a}chst mit einem einfachen, bereits etablierten Versuchsaufbau erstmalig die Bindung von FF an Nasengewebe im Vergleich zu anderen Glucocorticoiden in vitro untersucht. Die lipophileren Substanzen wie FF, MF und FP grenzten sich hierbei durch eine h{\"o}here Gewebebindung von den hydrophileren TCA und Bud ab. Es wurde ein neues Modell entwickelt, welches die pharmakokinetische Untersuchung zur Gewebebindung mit der Pharmakodynamik der Wirkstoffe in Form ihres antiinflammatorischen Effektes im Zellkulturmodell verkn{\"u}pfen sollte. So wurde wirkstoffges{\"a}ttigtes Gewebe einer extensiven Auswaschphase in Humanplasma ausgesetzt, um es anschließend mit humanen Lungenepithelzellen zu inkubieren. Es konnte gezeigt werden, dass alle Gewebeproben den Wirkstoff in das Zellkulturmedium freisetzten, was eine Hemmung der IL-8 Sekretion aus Lungenepithelzellen zur Folge hatte. Die St{\"a}rke des antiinflammatorischen Effektes der IL-8 Hemmung durch FF, FP, Bud und TCA entsprach der Kombination aus Geweberetention und intrinsischer Aktivit{\"a}t (Rezeptoraffinit{\"a}t) der Wirkstoffe. Gewebeproben des MF f{\"u}hrten zur geringsten IL-8 Hemmung, was durch die chemische Instabilit{\"a}t der Substanz erkl{\"a}rt werden konnte. Um eine weitere Ann{\"a}herung an physiologische Verh{\"a}ltnisse zu erreichen, wurde erfolgreich ein Modell entwickelt, welches nach Applikation der Suspension auf die Mukosa die pharmakokinetischen Abl{\"a}ufe simulieren sollte. Daf{\"u}r entscheidend war die Einbettung respiratorischen Gewebes in eine Gel-Matrix, wodurch eine zusammenh{\"a}ngende Mukosa-{\"a}hnliche Oberfl{\"a}che erreicht werden konnte. Als Modellsubstanzen wurden Bud aus Budes®-Nasenspray und FP aus Flutide® Nasal sowie als Vertreter der Antihistaminika Azelastin-HCl (AZ-HCl) aus Vividrin® akut eingesetzt. Es konnte gezeigt werden, dass die Gewebebindung des AZ-HCl im Vergleich zu den Glucocorticoiden am h{\"o}chsten war. Die gute Korrelation der Gewebebindung der Substanzen mit ihrem Verteilungsvolumen und der Vergleich von FP mit Bud zeigte die erfolgreiche Etablierung des Modells. Beide Glucocorticoide zeigten nach Applikation der Wirkstoffsuspension zun{\"a}chst eine {\"a}hnliche Assoziation an das Gewebe. Bei der Inkubation der Gewebe-Gel-Matrix mit Humanplasma wurde schließlich Fluticasonpropionat aus der Gewebe-Gel-Bindung im Vergleich zu Budesonid langsam freigesetzt. Weiterhin wurde im Gewebe-Gel-Modell die Bedeutung der Pharmakokinetik der Wirkstoffe auf die Pharmakodynamik ermittelt. Es wurden Freisetzungsproben der Gewebe-Gel-Matrices von AZ-HCl und FP auf ihre antiinflammatorische Aktivit{\"a}t untersucht. Die deutlich h{\"o}here Bindung des AZ-HCl an die Gewebe-Gel-Matrix {\"a}ußerte sich auch in h{\"o}heren Plasmakonzentrationen bei der Freisetzung im Vergleich zu FP. Jedoch konnte im Zellkulturmodell gezeigt werden, dass die Hemmung der IL-8 Freisetzung des FP, trotz der geringeren Konzentration in der Freisetzungsmatrix, das antiinflammatorische Potential des AZ-HCl {\"u}bertraf.},
  subject      = {Pharmakokinetik},
  language  = {de}
}
@article{SalvadorShityakovFoerster2013,
  author    = {Salvador, Ellaine and Shityakov, Sergey and F{\"o}rster, Carola},
  title     = {Glucocorticoids and endothelial cell barrier function},
  series = {Cell and Tissue Research},
  volume    = {355},
  journal   = {Cell and Tissue Research},
  number    = {3},
  doi       = {10.1007/s00441-013-1762-z},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-132091},
  pages     = {597-605},
  year      = {2013},
  abstract  = {Glucocorticoids (GCs) are steroid hormones that have inflammatory and immunosuppressive effects on a wide variety of cells. They are used as therapy for inflammatory disease and as a common agent against edema. The blood brain barrier (BBB), comprising microvascular endothelial cells, serves as a permeability screen between the blood and the brain. As such, it maintains homeostasis of the central nervous system (CNS). In many CNS disorders, BBB integrity is compromised. GC treatment has been demonstrated to improve the tightness of the BBB. The responses and effects of GCs are mediated by the ubiquitous GC receptor (GR). Ligand-bound GR recognizes and binds to the GC response element located within the promoter region of target genes. Transactivation of certain target genes leads to improved barrier properties of endothelial cells. In this review, we deal with the role of GCs in endothelial cell barrier function. First, we describe the mechanisms of GC action at the molecular level. Next, we discuss the regulation of the BBB by GCs, with emphasis on genes targeted by GCs such as occludin, claudins and VE-cadherin. Finally, we present currently available GC therapeutic strategies and their limitations.},
  language  = {en}
}
@article{NeuhausSchlundtFehrholzetal.2015,
  author    = {Neuhaus, Winfried and Schlundt, Marian and Fehrholz, Markus and Ehrke, Alexander and Kunzmann, Steffen and Liebner, Stefan and Speer, Christian P. and F{\"o}rster, Carola Y.},
  title     = {Multiple antenatal dexamethasone treatment alters brain vessel differentiation in newborn mouse pups},
  series = {PLoS ONE},
  volume    = {10},
  journal   = {PLoS ONE},
  number    = {8},
  doi       = {10.1371/journal.pone.0136221},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-148268},
  pages     = {e0136221},
  year      = {2015},
  abstract  = {Antenatal steroid treatment decreases morbidity and mortality in premature infants through the maturation of lung tissue, which enables sufficient breathing performance. However, clinical and animal studies have shown that repeated doses of glucocorticoids such as dexamethasone and betamethasone lead to long-term adverse effects on brain development. Therefore, we established a mouse model for antenatal dexamethasone treatment to investigate the effects of dexamethasone on brain vessel differentiation towards the blood-brain barrier (BBB) phenotype, focusing on molecular marker analysis. The major findings were that in total brains on postnatal day (PN) 4 triple antenatal dexamethasone treatment significantly downregulated the tight junction protein claudin-5, the endothelial marker Pecam-1/CD31, the glucocorticoid receptor, the NR1 subunit of the N-methyl-D-aspartate receptor, and Abc transporters (Abcb1a, Abcg2 Abcc4). Less pronounced effects were found after single antenatal dexamethasone treatment and in PN10 samples. Comparisons of total brain samples with isolated brain endothelial cells together with the stainings for Pecam-1/CD31 and claudin-5 led to the assumption that the morphology of brain vessels is affected by antenatal dexamethasone treatment at PN4. On the mRNA level markers for angiogenesis, the sonic hedgehog and the Wnt pathway were downregulated in PN4 samples, suggesting fundamental changes in brain vascularization and/or differentiation. In conclusion, we provided a first comprehensive molecular basis for the adverse effects of multiple antenatal dexamethasone treatment on brain vessel differentiation.},
  language  = {en}
}
@article{ZannasArlothCarrilloRoaetal.2015,
  author    = {Zannas, Anthony S. and Arloth, Janine and Carrillo-Roa, Tania and Iurato, Stella and R{\"o}h, Simone and Ressler, Kerry J. and Nemeroff, Charles B. and Smith, Alicia K. and Bradley, Bekh and Heim, Christine and Menke, Andreas and Lange, Jennifer F. and Br{\"u}ckl, Tanja and Ising, Marcus and Wray, Naomi R. and Erhardt, Angelika and Binder, Elisabeth B. and Mehta, Divya},
  title     = {Lifetime stress accelerates epigenetic aging in an urban, African American cohort: relevance of glucocorticoid signaling},
  series = {Genome Biology},
  volume    = {16},
  journal   = {Genome Biology},
  number    = {266},
  doi       = {10.1186/s13059-015-0828-5},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-149865},
  year      = {2015},
  abstract  = {Background Chronic psychological stress is associated with accelerated aging and increased risk for aging-related diseases, but the underlying molecular mechanisms are unclear. Results We examined the effect of lifetime stressors on a DNA methylation-based age predictor, epigenetic clock. After controlling for blood cell-type composition and lifestyle parameters, cumulative lifetime stress, but not childhood maltreatment or current stress alone, predicted accelerated epigenetic aging in an urban, African American cohort (n = 392). This effect was primarily driven by personal life stressors, was more pronounced with advancing age, and was blunted in individuals with higher childhood abuse exposure. Hypothesizing that these epigenetic effects could be mediated by glucocorticoid signaling, we found that a high number (n = 85) of epigenetic clock CpG sites were located within glucocorticoid response elements. We further examined the functional effects of glucocorticoids on epigenetic clock CpGs in an independent sample with genome-wide DNA methylation (n = 124) and gene expression data (n = 297) before and after exposure to the glucocorticoid receptor agonist dexamethasone. Dexamethasone induced dynamic changes in methylation in 31.2 \% (110/353) of these CpGs and transcription in 81.7 \% (139/170) of genes neighboring epigenetic clock CpGs. Disease enrichment analysis of these dexamethasone-regulated genes showed enriched association for aging-related diseases, including coronary artery disease, arteriosclerosis, and leukemias. Conclusions Cumulative lifetime stress may accelerate epigenetic aging, an effect that could be driven by glucocorticoid-induced epigenetic changes. These findings contribute to our understanding of mechanisms linking chronic stress with accelerated aging and heightened disease risk.},
  language  = {en}
}
@article{FehrholzGlaserSpeeretal.2017,
  author    = {Fehrholz, Markus and Glaser, Kirsten and Speer, Christian P. and Seidenspinner, Silvia and Ottensmeier, Barbara and Kunzmann, Steffen},
  title     = {Caffeine modulates glucocorticoid-induced expression of CTGF in lung epithelial cells and fibroblasts},
  series = {Respiratory Research},
  volume    = {18},
  journal   = {Respiratory Research},
  number    = {51},
  doi       = {10.1186/s12931-017-0535-8},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-157672},
  year      = {2017},
  abstract  = {Background: Although caffeine and glucocorticoids are frequently used to treat chronic lung disease in preterm neonates, potential interactions are largely unknown. While anti-inflammatory effects of glucocorticoids are well defined, their impact on airway remodeling is less characterized. Caffeine has been ascribed to positive effects on airway inflammation as well as remodeling. Connective tissue growth factor (CTGF, CCN2) plays a key role in airway remodeling and has been implicated in the pathogenesis of chronic lung diseases such as bronchopulmonary dysplasia (BPD) in preterm infants. The current study addressed the impact of glucocorticoids on the regulation of CTGF in the presence of caffeine using human lung epithelial and fibroblast cells. Methods: The human airway epithelial cell line H441 and the fetal lung fibroblast strain IMR-90 were exposed to different glucocorticoids (dexamethasone, budesonide, betamethasone, prednisolone, hydrocortisone) and caffeine. mRNA and protein expression of CTGF, TGF-β1-3, and TNF-α were determined by means of quantitative real-time PCR and immunoblotting. H441 cells were additionally treated with cAMP, the adenylyl cyclase activator forskolin, and the selective phosphodiesterase (PDE)-4 inhibitor cilomilast to mimic caffeine-mediated PDE inhibition. Results: Treatment with different glucocorticoids (1 μM) significantly increased CTGF mRNA levels in H441 (p < 0.0001) and IMR-90 cells (p < 0.01). Upon simultaneous exposure to caffeine (10 mM), both glucocorticoid-induced mRNA and protein expression were significantly reduced in IMR-90 cells (p < 0.0001). Of note, 24 h exposure to caffeine alone significantly suppressed basal expression of CTGF mRNA and protein in IMR-90 cells. Caffeine-induced reduction of CTGF mRNA expression seemed to be independent of cAMP levels, adenylyl cyclase activation, or PDE-4 inhibition. While dexamethasone or caffeine treatment did not affect TGF-β1 mRNA in H441 cells, increased expression of TGF-β2 and TGF-β3 mRNA was detected upon exposure to dexamethasone or dexamethasone and caffeine, respectively. Moreover, caffeine increased TNF-α mRNA in H441 cells (6.5 ± 2.2-fold, p < 0.05) which has been described as potent inhibitor of CTGF expression. Conclusions: In addition to well-known anti-inflammatory features, glucocorticoids may have adverse effects on long-term remodeling by TGF-β1-independent induction of CTGF in lung cells. Simultaneous treatment with caffeine may attenuate glucocorticoid-induced expression of CTGF, thereby promoting restoration of lung homeostasis.},
  language  = {en}
}